2ndAP helps eligible U.S. and Canadian research-use-only peptide businesses explore a transparent, partner-supported path to card processing. The program includes ongoing website compliance monitoring, preset terms, and separate underwriting review; meeting compliance requirements does not guarantee approval.

Card-brand restrictions on peptide merchants are creating serious consequences throughout the payments industry. Learn how potential six-figure fines against acquiring banks and processors can lead to frozen funds, sudden account closures, and fewer processing options for peptide businesses.

Eli Lilly’s tirzepatide patent should not become a blanket ban on peptide processing. We examine Visa’s penalties, corporate pressure, and the growing threat of financial deplatforming.

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.

Reliable payment processing is critical for peptide businesses. Learn how 2nd Amendment Processing helps peptide merchants overcome industry challenges with secure, scalable payment solutions. #ProcessWithPurpose